MT Newswires
Vaxcyte Completes Patient Enrollment in OPUS-1, OPUS-2 Phase-3 Trials for Pneumonia Vaccine
📊
AI Sentiment
Positive
6/10
- Home
- PCVX
PCVX
Vaxcyte Inc.
as of 03-23-2026 3:37pm EST
$56.24
+$2.36
+4.38%
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 6.1B | IPO Year: | 2020 |
| Target Price: | $98.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | quarterly |
| EPS: | -5.63 | EPS Growth: | -48.16 |
| 52 Week Low/High: | $28.09 - $73.82 | Next Earning Date: | 05-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -9.57 | Index: | N/A |
| Free Cash Flow: | -669290000.0 | FCF Growth: | N/A |
AI-Powered PCVX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 82.09%
82.09%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
Cowan Elvia
Sell
SVP, Finance & CAO
PCVX Mar 17, 2026
Avg Cost/Share
$55.83
Shares
1,892
Total Value
$105,146.98
Owned After
29,380
Cowan Elvia
Sell
SVP, Finance & CAO
PCVX Mar 11, 2026
Avg Cost/Share
$58.59
Shares
2,500
Total Value
$146,481.75
Owned After
29,380
SEC Form 4
Wassil Jim
Sell
CHIEF OPERATING OFFICER
PCVX Mar 10, 2026
Avg Cost/Share
$58.74
Shares
7,395
Total Value
$435,439.81
Owned After
171,786
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cowan Elvia | PCVX | SVP, Finance & CAO | Mar 17, 2026 | Sell | $55.83 | 1,892 | $105,146.98 | 29,380 | |
| Cowan Elvia | PCVX | SVP, Finance & CAO | Mar 11, 2026 | Sell | $58.59 | 2,500 | $146,481.75 | 29,380 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Mar 10, 2026 | Sell | $58.74 | 7,395 | $435,439.81 | 171,786 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
AI Prediction SELL
1D
-4.51%
$58.58
Act: +2.75%
5D
-7.98%
$56.46
Act: -2.49%
20D
-8.45%
$56.16
Price: $61.35 Prob +5D: 0% AUC: 1.000
0001649094-26-000005
pcvx-202602240001649094FALSE00016490942026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026
Vaxcyte, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware01-3932346-4233385 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
825 Industrial Road Suite 300 San Carlos , California 94070 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 837-0111 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per sharePCVXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit NumberDescription 99.1Press Release of Vaxcyte, Inc., dated February 24, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VAXCYTE, INC.
Date:February 24, 2026By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0001649094-25-000112
pcvx-202511040001649094FALSE00016490942025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
Vaxcyte, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware01-3932346-4233385 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
825 Industrial Road Suite 300 San Carlos , California 94070 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 837-0111 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per sharePCVXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit NumberDescription 99.1Press Release of Vaxcyte, Inc., dated November 4, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VAXCYTE, INC.
Date:November 4, 2025By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001649094-25-000096
pcvx-202508060001649094FALSE00016490942025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
Vaxcyte, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware01-3932346-4233385 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
825 Industrial Road Suite 300 San Carlos , California 94070 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 837-0111 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per sharePCVXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit NumberDescription 99.1Press Release of Vaxcyte, Inc., dated August 6, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VAXCYTE, INC.
Date:August 6, 2025By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
📈
AI Sentiment
Highly Positive
10/10
Compare PCVX vs Leading Stocks
See how PCVX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.